Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: An analysis of the PROGRESS and ADVANCEtrials

Emily R. Atkins, Yoichiro Hirakawa, Abdul Salam, Mark Woodward, Mark Cooper, Pavel Hamet, Stephen Harrap, Kennedy Lees, Lisheng Liu, Giuseppe Mancia, Michel Marre, Vlado Perkovic, Neil Poulter, Bryan Williams, John Chalmers, Anthony Rodgers

Research output: Contribution to journalArticle

Abstract

Objective: To measure the placebo-controlled effects of combination therapy on hypotension, treatment discontinuation, and major renal outcomes, according to baseline blood pressure. Methods: We conducted an analysis of the action in diabetes and vascular disease: preterax and diamicron-MR controlled evaluation ADVANCE and perindopril protection against recurrent stroke study PROGRESS trials, including 14 684 participants allocated combination therapy or placebo. The mean age was 65 years, 61% were men, and 64% were receiving background blood pressure lowering (BPL) therapy. Participants were stratified into five subgroups by baseline SBP less than 120, 120-129, 130-139, 140-159, and at least 160 mmHg. Discontinuation of study treatment during the active run-in phase and postrandomization follow-up was assessed for hypotension/dizziness and other causes. Major renal outcomes (sustained doubling in creatinine or renal death) were also assessed. Results: Discontinuation during the 4-6-week active runin phase due to hypotension/dizziness ranged from 3.6% in those with SBP less than 120mmHg to 1.3% in those with SBP at least 160 mmHg. Median follow-up in the randomized phase was 5.6 years, and discontinuation for hypotension was higher with combination therapy compared with placebo in the less than 120mmHg group (4.7 vs. 1.2%). However, for each subgroup with baseline SBP 120-129, 130-139, and 140-159 mmHg, the absolute excess of discontinuation due to hypotension with combination therapy was 0.7%. Total discontinuations were only increased in the less than 120mmHg group (18.4 vs. 12.5%) and the 120-129-mmHg subgroup (17.6 vs. 14.2%). There were no clear differences across the SBP subgroups for the combined renal outcome (overall, 0.8 vs. 0.6%). Conclusion: Compared with those with baseline SBP 140-159 mmHg, side effects of dual combination BPL are essentially the same for people with SBP 130-139mmHg and only modestly increased among patients with SBP 120-129 mmHg. During long-term therapy, side effects sufficient to stop treatment that are treatment related (i.e. occur in excess of rates seen with placebo) occur at less than 0.5%/year in patients with baseline SBP 120-139 mmHg. These results have important implications in assessing the likely balance of benefits and side effects of BPL with combination therapy among those with SBP 120-139 mmHg.

Original languageEnglish
Pages (from-to)1318-1325
Number of pages8
JournalJournal of Hypertension
Volume35
Issue number6
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Blood Pressure
Hypotension
Therapeutics
Kidney
perindopril drug combination indapamide
Placebos
Dizziness
Gliclazide
Perindopril
Placebo Effect
Vascular Diseases
Creatinine
Stroke

Keywords

  • Blood pressure
  • Combination therapy
  • Cough
  • Discontinuation
  • Hypotension
  • Tolerability

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Side effects and tolerability of combination blood pressure lowering according to blood pressure levels : An analysis of the PROGRESS and ADVANCEtrials. / Atkins, Emily R.; Hirakawa, Yoichiro; Salam, Abdul; Woodward, Mark; Cooper, Mark; Hamet, Pavel; Harrap, Stephen; Lees, Kennedy; Liu, Lisheng; Mancia, Giuseppe; Marre, Michel; Perkovic, Vlado; Poulter, Neil; Williams, Bryan; Chalmers, John; Rodgers, Anthony.

In: Journal of Hypertension, Vol. 35, No. 6, 01.01.2017, p. 1318-1325.

Research output: Contribution to journalArticle

Atkins, ER, Hirakawa, Y, Salam, A, Woodward, M, Cooper, M, Hamet, P, Harrap, S, Lees, K, Liu, L, Mancia, G, Marre, M, Perkovic, V, Poulter, N, Williams, B, Chalmers, J & Rodgers, A 2017, 'Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: An analysis of the PROGRESS and ADVANCEtrials', Journal of Hypertension, vol. 35, no. 6, pp. 1318-1325. https://doi.org/10.1097/HJH.0000000000001287
Atkins, Emily R. ; Hirakawa, Yoichiro ; Salam, Abdul ; Woodward, Mark ; Cooper, Mark ; Hamet, Pavel ; Harrap, Stephen ; Lees, Kennedy ; Liu, Lisheng ; Mancia, Giuseppe ; Marre, Michel ; Perkovic, Vlado ; Poulter, Neil ; Williams, Bryan ; Chalmers, John ; Rodgers, Anthony. / Side effects and tolerability of combination blood pressure lowering according to blood pressure levels : An analysis of the PROGRESS and ADVANCEtrials. In: Journal of Hypertension. 2017 ; Vol. 35, No. 6. pp. 1318-1325.
@article{df3404afefd4497e9ee32f3203d1e39f,
title = "Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: An analysis of the PROGRESS and ADVANCEtrials",
abstract = "Objective: To measure the placebo-controlled effects of combination therapy on hypotension, treatment discontinuation, and major renal outcomes, according to baseline blood pressure. Methods: We conducted an analysis of the action in diabetes and vascular disease: preterax and diamicron-MR controlled evaluation ADVANCE and perindopril protection against recurrent stroke study PROGRESS trials, including 14 684 participants allocated combination therapy or placebo. The mean age was 65 years, 61{\%} were men, and 64{\%} were receiving background blood pressure lowering (BPL) therapy. Participants were stratified into five subgroups by baseline SBP less than 120, 120-129, 130-139, 140-159, and at least 160 mmHg. Discontinuation of study treatment during the active run-in phase and postrandomization follow-up was assessed for hypotension/dizziness and other causes. Major renal outcomes (sustained doubling in creatinine or renal death) were also assessed. Results: Discontinuation during the 4-6-week active runin phase due to hypotension/dizziness ranged from 3.6{\%} in those with SBP less than 120mmHg to 1.3{\%} in those with SBP at least 160 mmHg. Median follow-up in the randomized phase was 5.6 years, and discontinuation for hypotension was higher with combination therapy compared with placebo in the less than 120mmHg group (4.7 vs. 1.2{\%}). However, for each subgroup with baseline SBP 120-129, 130-139, and 140-159 mmHg, the absolute excess of discontinuation due to hypotension with combination therapy was 0.7{\%}. Total discontinuations were only increased in the less than 120mmHg group (18.4 vs. 12.5{\%}) and the 120-129-mmHg subgroup (17.6 vs. 14.2{\%}). There were no clear differences across the SBP subgroups for the combined renal outcome (overall, 0.8 vs. 0.6{\%}). Conclusion: Compared with those with baseline SBP 140-159 mmHg, side effects of dual combination BPL are essentially the same for people with SBP 130-139mmHg and only modestly increased among patients with SBP 120-129 mmHg. During long-term therapy, side effects sufficient to stop treatment that are treatment related (i.e. occur in excess of rates seen with placebo) occur at less than 0.5{\%}/year in patients with baseline SBP 120-139 mmHg. These results have important implications in assessing the likely balance of benefits and side effects of BPL with combination therapy among those with SBP 120-139 mmHg.",
keywords = "Blood pressure, Combination therapy, Cough, Discontinuation, Hypotension, Tolerability",
author = "Atkins, {Emily R.} and Yoichiro Hirakawa and Abdul Salam and Mark Woodward and Mark Cooper and Pavel Hamet and Stephen Harrap and Kennedy Lees and Lisheng Liu and Giuseppe Mancia and Michel Marre and Vlado Perkovic and Neil Poulter and Bryan Williams and John Chalmers and Anthony Rodgers",
year = "2017",
month = "1",
day = "1",
doi = "10.1097/HJH.0000000000001287",
language = "English",
volume = "35",
pages = "1318--1325",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Side effects and tolerability of combination blood pressure lowering according to blood pressure levels

T2 - An analysis of the PROGRESS and ADVANCEtrials

AU - Atkins, Emily R.

AU - Hirakawa, Yoichiro

AU - Salam, Abdul

AU - Woodward, Mark

AU - Cooper, Mark

AU - Hamet, Pavel

AU - Harrap, Stephen

AU - Lees, Kennedy

AU - Liu, Lisheng

AU - Mancia, Giuseppe

AU - Marre, Michel

AU - Perkovic, Vlado

AU - Poulter, Neil

AU - Williams, Bryan

AU - Chalmers, John

AU - Rodgers, Anthony

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objective: To measure the placebo-controlled effects of combination therapy on hypotension, treatment discontinuation, and major renal outcomes, according to baseline blood pressure. Methods: We conducted an analysis of the action in diabetes and vascular disease: preterax and diamicron-MR controlled evaluation ADVANCE and perindopril protection against recurrent stroke study PROGRESS trials, including 14 684 participants allocated combination therapy or placebo. The mean age was 65 years, 61% were men, and 64% were receiving background blood pressure lowering (BPL) therapy. Participants were stratified into five subgroups by baseline SBP less than 120, 120-129, 130-139, 140-159, and at least 160 mmHg. Discontinuation of study treatment during the active run-in phase and postrandomization follow-up was assessed for hypotension/dizziness and other causes. Major renal outcomes (sustained doubling in creatinine or renal death) were also assessed. Results: Discontinuation during the 4-6-week active runin phase due to hypotension/dizziness ranged from 3.6% in those with SBP less than 120mmHg to 1.3% in those with SBP at least 160 mmHg. Median follow-up in the randomized phase was 5.6 years, and discontinuation for hypotension was higher with combination therapy compared with placebo in the less than 120mmHg group (4.7 vs. 1.2%). However, for each subgroup with baseline SBP 120-129, 130-139, and 140-159 mmHg, the absolute excess of discontinuation due to hypotension with combination therapy was 0.7%. Total discontinuations were only increased in the less than 120mmHg group (18.4 vs. 12.5%) and the 120-129-mmHg subgroup (17.6 vs. 14.2%). There were no clear differences across the SBP subgroups for the combined renal outcome (overall, 0.8 vs. 0.6%). Conclusion: Compared with those with baseline SBP 140-159 mmHg, side effects of dual combination BPL are essentially the same for people with SBP 130-139mmHg and only modestly increased among patients with SBP 120-129 mmHg. During long-term therapy, side effects sufficient to stop treatment that are treatment related (i.e. occur in excess of rates seen with placebo) occur at less than 0.5%/year in patients with baseline SBP 120-139 mmHg. These results have important implications in assessing the likely balance of benefits and side effects of BPL with combination therapy among those with SBP 120-139 mmHg.

AB - Objective: To measure the placebo-controlled effects of combination therapy on hypotension, treatment discontinuation, and major renal outcomes, according to baseline blood pressure. Methods: We conducted an analysis of the action in diabetes and vascular disease: preterax and diamicron-MR controlled evaluation ADVANCE and perindopril protection against recurrent stroke study PROGRESS trials, including 14 684 participants allocated combination therapy or placebo. The mean age was 65 years, 61% were men, and 64% were receiving background blood pressure lowering (BPL) therapy. Participants were stratified into five subgroups by baseline SBP less than 120, 120-129, 130-139, 140-159, and at least 160 mmHg. Discontinuation of study treatment during the active run-in phase and postrandomization follow-up was assessed for hypotension/dizziness and other causes. Major renal outcomes (sustained doubling in creatinine or renal death) were also assessed. Results: Discontinuation during the 4-6-week active runin phase due to hypotension/dizziness ranged from 3.6% in those with SBP less than 120mmHg to 1.3% in those with SBP at least 160 mmHg. Median follow-up in the randomized phase was 5.6 years, and discontinuation for hypotension was higher with combination therapy compared with placebo in the less than 120mmHg group (4.7 vs. 1.2%). However, for each subgroup with baseline SBP 120-129, 130-139, and 140-159 mmHg, the absolute excess of discontinuation due to hypotension with combination therapy was 0.7%. Total discontinuations were only increased in the less than 120mmHg group (18.4 vs. 12.5%) and the 120-129-mmHg subgroup (17.6 vs. 14.2%). There were no clear differences across the SBP subgroups for the combined renal outcome (overall, 0.8 vs. 0.6%). Conclusion: Compared with those with baseline SBP 140-159 mmHg, side effects of dual combination BPL are essentially the same for people with SBP 130-139mmHg and only modestly increased among patients with SBP 120-129 mmHg. During long-term therapy, side effects sufficient to stop treatment that are treatment related (i.e. occur in excess of rates seen with placebo) occur at less than 0.5%/year in patients with baseline SBP 120-139 mmHg. These results have important implications in assessing the likely balance of benefits and side effects of BPL with combination therapy among those with SBP 120-139 mmHg.

KW - Blood pressure

KW - Combination therapy

KW - Cough

KW - Discontinuation

KW - Hypotension

KW - Tolerability

UR - http://www.scopus.com/inward/record.url?scp=85011797675&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011797675&partnerID=8YFLogxK

U2 - 10.1097/HJH.0000000000001287

DO - 10.1097/HJH.0000000000001287

M3 - Article

C2 - 28169881

AN - SCOPUS:85011797675

VL - 35

SP - 1318

EP - 1325

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 6

ER -